I CARE — skin side effects from cancer immunotherapy
Full Project 2: I CARE (Immunotherapy Cutaneous Adverse events Research)
This project looks at why people treated with cancer immunotherapy get inflammatory skin side effects and how biological and social factors change how severe they are and how well people recover.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11194509 on NIH RePORTER |
What this research studies
As someone getting cancer immunotherapy, this project asks why the treatment sometimes causes inflammatory skin problems and who is most likely to have worse outcomes. Doctors will collect skin tissue, blood tests, and information about stress, health history, and social supports to link immune markers (like certain immune cells and genes) with real-world challenges. The team will use those findings to identify people at high risk and to tailor counseling and supportive-care approaches, with special attention to patients with limited socioeconomic resources. The overall aim is to prevent severe skin reactions, keep people on their cancer treatments when safe, and reduce complications that lower quality of life.
Who could benefit from this research
Good fit: Ideal candidates are people who are starting or receiving immune checkpoint inhibitor therapy and who may be at higher risk for immune-related skin side effects, including those with prior autoimmune conditions or limited social resources.
Not a fit: People who are not receiving immune checkpoint inhibitors or whose treatment side effects do not involve the skin are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could help predict and prevent severe skin reactions to immunotherapy and guide better support so more patients can stay on effective cancer treatment with fewer complications.
How similar studies have performed: Previous studies have linked immune markers like HLA types, eosinophils, and B cell levels to immune-related side effects, but interventions to reduce harm—especially in disadvantaged populations—remain largely unproven.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Shah, Neil J — Sloan-Kettering Inst Can Research
- Study coordinator: Shah, Neil J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.